Moving beyond simple answers to complex disorders in sarcomeric cardiomyopathies: the role of integrated systems

Andrea E. Deranek, Matthew M. Klass, Jil C Tardiff

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The classic clinical definition of hypertrophic cardiomyopathy (HCM) as originally described by Teare is deceptively simple, “left ventricular hypertrophy in the absence of any identifiable cause.” Longitudinal studies, however, including a seminal study performed by Frank and Braunwald in 1968, clearly described the disorder much as we know it today, a complex, progressive, and highly variable cardiomyopathy affecting ~ 1/500 individuals worldwide. Subsequent genetic linkage studies in the early 1990s identified mutations in virtually all of the protein components of the cardiac sarcomere as the primary molecular cause of HCM. In addition, a substantial proportion of inherited dilated cardiomyopathy (DCM) has also been linked to sarcomeric protein mutations. Despite our deep understanding of the overall function of the sarcomere as the primary driver of cardiac contractility, the ability to use genotype in patient management remains elusive. A persistent challenge in the field from both the biophysical and clinical standpoints is how to rigorously link high-resolution protein dynamics and mechanics to the long-term cardiovascular remodeling process that characterizes these complex disorders. In this review, we will explore the depth of the problem from both the standpoint of a multi-subunit, highly conserved and dynamic “machine” to the resultant clinical and structural human phenotype with an emphasis on new, integrative approaches that can be widely applied to identify both novel disease mechanisms and new therapeutic targets for these primary biophysical disorders of the cardiac sarcomere.

Original languageEnglish (US)
JournalPflugers Archiv European Journal of Physiology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Sarcomeres
Cardiomyopathies
Hypertrophic Cardiomyopathy
Mutation
Proteins
Genetic Linkage
Dilated Cardiomyopathy
Left Ventricular Hypertrophy
Mechanics
Longitudinal Studies
Genotype
Phenotype
Therapeutics

Keywords

  • Dilated cardiomyopathy
  • Hypertrophic cardiomyopathy
  • Thin filament
  • Tropomyosin
  • Troponin

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Physiology (medical)

Cite this

Moving beyond simple answers to complex disorders in sarcomeric cardiomyopathies : the role of integrated systems. / Deranek, Andrea E.; Klass, Matthew M.; Tardiff, Jil C.

In: Pflugers Archiv European Journal of Physiology, 01.01.2019.

Research output: Contribution to journalReview article

@article{c2de1b6733bc4b0ca5550fd7e25bd8d7,
title = "Moving beyond simple answers to complex disorders in sarcomeric cardiomyopathies: the role of integrated systems",
abstract = "The classic clinical definition of hypertrophic cardiomyopathy (HCM) as originally described by Teare is deceptively simple, “left ventricular hypertrophy in the absence of any identifiable cause.” Longitudinal studies, however, including a seminal study performed by Frank and Braunwald in 1968, clearly described the disorder much as we know it today, a complex, progressive, and highly variable cardiomyopathy affecting ~ 1/500 individuals worldwide. Subsequent genetic linkage studies in the early 1990s identified mutations in virtually all of the protein components of the cardiac sarcomere as the primary molecular cause of HCM. In addition, a substantial proportion of inherited dilated cardiomyopathy (DCM) has also been linked to sarcomeric protein mutations. Despite our deep understanding of the overall function of the sarcomere as the primary driver of cardiac contractility, the ability to use genotype in patient management remains elusive. A persistent challenge in the field from both the biophysical and clinical standpoints is how to rigorously link high-resolution protein dynamics and mechanics to the long-term cardiovascular remodeling process that characterizes these complex disorders. In this review, we will explore the depth of the problem from both the standpoint of a multi-subunit, highly conserved and dynamic “machine” to the resultant clinical and structural human phenotype with an emphasis on new, integrative approaches that can be widely applied to identify both novel disease mechanisms and new therapeutic targets for these primary biophysical disorders of the cardiac sarcomere.",
keywords = "Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Thin filament, Tropomyosin, Troponin",
author = "Deranek, {Andrea E.} and Klass, {Matthew M.} and Tardiff, {Jil C}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00424-019-02269-0",
language = "English (US)",
journal = "Pflugers Archiv European Journal of Physiology",
issn = "0031-6768",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Moving beyond simple answers to complex disorders in sarcomeric cardiomyopathies

T2 - the role of integrated systems

AU - Deranek, Andrea E.

AU - Klass, Matthew M.

AU - Tardiff, Jil C

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The classic clinical definition of hypertrophic cardiomyopathy (HCM) as originally described by Teare is deceptively simple, “left ventricular hypertrophy in the absence of any identifiable cause.” Longitudinal studies, however, including a seminal study performed by Frank and Braunwald in 1968, clearly described the disorder much as we know it today, a complex, progressive, and highly variable cardiomyopathy affecting ~ 1/500 individuals worldwide. Subsequent genetic linkage studies in the early 1990s identified mutations in virtually all of the protein components of the cardiac sarcomere as the primary molecular cause of HCM. In addition, a substantial proportion of inherited dilated cardiomyopathy (DCM) has also been linked to sarcomeric protein mutations. Despite our deep understanding of the overall function of the sarcomere as the primary driver of cardiac contractility, the ability to use genotype in patient management remains elusive. A persistent challenge in the field from both the biophysical and clinical standpoints is how to rigorously link high-resolution protein dynamics and mechanics to the long-term cardiovascular remodeling process that characterizes these complex disorders. In this review, we will explore the depth of the problem from both the standpoint of a multi-subunit, highly conserved and dynamic “machine” to the resultant clinical and structural human phenotype with an emphasis on new, integrative approaches that can be widely applied to identify both novel disease mechanisms and new therapeutic targets for these primary biophysical disorders of the cardiac sarcomere.

AB - The classic clinical definition of hypertrophic cardiomyopathy (HCM) as originally described by Teare is deceptively simple, “left ventricular hypertrophy in the absence of any identifiable cause.” Longitudinal studies, however, including a seminal study performed by Frank and Braunwald in 1968, clearly described the disorder much as we know it today, a complex, progressive, and highly variable cardiomyopathy affecting ~ 1/500 individuals worldwide. Subsequent genetic linkage studies in the early 1990s identified mutations in virtually all of the protein components of the cardiac sarcomere as the primary molecular cause of HCM. In addition, a substantial proportion of inherited dilated cardiomyopathy (DCM) has also been linked to sarcomeric protein mutations. Despite our deep understanding of the overall function of the sarcomere as the primary driver of cardiac contractility, the ability to use genotype in patient management remains elusive. A persistent challenge in the field from both the biophysical and clinical standpoints is how to rigorously link high-resolution protein dynamics and mechanics to the long-term cardiovascular remodeling process that characterizes these complex disorders. In this review, we will explore the depth of the problem from both the standpoint of a multi-subunit, highly conserved and dynamic “machine” to the resultant clinical and structural human phenotype with an emphasis on new, integrative approaches that can be widely applied to identify both novel disease mechanisms and new therapeutic targets for these primary biophysical disorders of the cardiac sarcomere.

KW - Dilated cardiomyopathy

KW - Hypertrophic cardiomyopathy

KW - Thin filament

KW - Tropomyosin

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=85062788474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062788474&partnerID=8YFLogxK

U2 - 10.1007/s00424-019-02269-0

DO - 10.1007/s00424-019-02269-0

M3 - Review article

C2 - 30848350

AN - SCOPUS:85062788474

JO - Pflugers Archiv European Journal of Physiology

JF - Pflugers Archiv European Journal of Physiology

SN - 0031-6768

ER -